Pathology & Oncology Research

, Volume 16, Issue 2, pp 143–148 | Cite as

Panitumumab: An Arrow on Target

Article

Abstract

Several options are available today in the treatment of advanced colorectal cancer: traditional chemotherapeutic regimens, targeted therapies, and their combinations. Panitumumab is a new, fully human anti-EGFR monoclonal antibody, what is well-tolerated, effective as a single agent in chemotherapy refractory patients and in different combinations. The clinical response is restricted to tumors with wild-type RAS, therefore the RAS status should be checked before treatment.

Keywords

Panitumumab Colorectal cancer Anti-EGFR therapy 

References

  1. 1.
    Foon KA, Yang XD, Weiner LM et al (2004) Preclinical and clinical evaluation of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 58:984–990PubMedGoogle Scholar
  2. 2.
    Jakobovits A, Amado RG, Yang X et al (2007) From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 25:1134–1143CrossRefPubMedGoogle Scholar
  3. 3.
    Freeman D, McDorman K, Bussh T et al (2004) Mono and combination-therapeutic activity of panitumumab (ABX-EGF) on human A431 epidermoid and HT-29 colon carcinoma xenografts: correlation with pharmacodynamic parameters. Proc Am Assoc Cancer Res 27–31Google Scholar
  4. 4.
    Lopez-Albaitero A, Ferris RL (2007) Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngeal Head Neck Surg 133:1277–1281CrossRefGoogle Scholar
  5. 5.
    Siena S, Sartore-Bianchi A, Di Nicolantonio F et al (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101:1308–1324CrossRefPubMedGoogle Scholar
  6. 6.
    Barault L, Veyrie N, Jooste V et al (2008) Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colonic cancer. Int J Cancer 122:2255–2259CrossRefPubMedGoogle Scholar
  7. 7.
    Artale S, Sartore-Bianchi A, Veronese S et al (2008) Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 26:4217–4219CrossRefPubMedGoogle Scholar
  8. 8.
    Andreyev HJ, Norman AR, Cunningham D et al (2001) Kirsten ras mutation in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer 85:692–696CrossRefPubMedGoogle Scholar
  9. 9.
    Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared to best supportive care alone in patients with chemotherapy-refractory a metastatic colorectal cancer. J Clin Oncol 25:1658–1664CrossRefPubMedGoogle Scholar
  10. 10.
    Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634CrossRefPubMedGoogle Scholar
  11. 11.
    Roth A, Tejpar S, Yan P et al (2009) Correlation of molecular markers in colon cancer with stage-specific prognosis: results of the translational study on the PETACC 3-EORTC 40093-SAKK 60-00 trial. ASCO, Gastrointestinal cancers Symposium, San Francisco, abstract 288Google Scholar
  12. 12.
    Moroni M, Veronese S, Benvenuti S et al (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279–286CrossRefPubMedGoogle Scholar
  13. 13.
    Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643–2648CrossRefPubMedGoogle Scholar
  14. 14.
    Lievre A, Bachet JB, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995CrossRefPubMedGoogle Scholar
  15. 15.
    Monzon FA, Ogino S, Hammond EH et al (2009) The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 133:1600–1606PubMedGoogle Scholar
  16. 16.
    Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705–5712CrossRefPubMedGoogle Scholar
  17. 17.
    Sartore-Bianchi A, Martini M, Molinari F et al (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69:1851–1857CrossRefPubMedGoogle Scholar
  18. 18.
    Prenen H, De Schutter J, Jacobs B et al (2009) PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 15:3184–3188CrossRefPubMedGoogle Scholar
  19. 19.
    Benvenuti S, Frattini M, Arena S et al (2008) PIK3CAcancer mutations display gender and tissue specificity patterns. Hum Mutat 29:284–288CrossRefPubMedGoogle Scholar
  20. 20.
    Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417CrossRefPubMedGoogle Scholar
  21. 21.
    Sartore-Bianchi A, Moroni M, Veronese S et al (2007) Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25:3238–3245CrossRefPubMedGoogle Scholar
  22. 22.
    Rowinsky EK, Schwartz GH, Gollob JA et al (2004) Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cancer. J Clin Oncol 22:3003–3015CrossRefPubMedGoogle Scholar
  23. 23.
    Weiner LM, Belldegrun AS, Crawford J et al (2008) Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 14:502–508CrossRefPubMedGoogle Scholar
  24. 24.
    Lynch TJJ, Kim ES, Eaby B et al (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12:610–621CrossRefPubMedGoogle Scholar
  25. 25.
    Arends R, Yang B, Schwab G et al (2005) Flexible dosing schedules of panitumumab in cancer patients. J Clin Oncol 23, abstract 3089Google Scholar
  26. 26.
    Berlin J, Posex J, Tchekmedyian S et al (2007) Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 6:427–432CrossRefPubMedGoogle Scholar
  27. 27.
    Hecht JR, Patnaik A, Berlin J et al (2007) Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110:980–988CrossRefPubMedGoogle Scholar
  28. 28.
    Mitchell EP, Hecht JR, Baranda J et al (2007) Panitumumab activity in metastatic colorectal cancer (mCRC) petients (pts) with low or negative tumor epidermal growth factor receptor (EGFRr) levels: An updated analysis. J Clin Oncol 25, abstract 4082Google Scholar
  29. 29.
    Doi T, Ohtsu A, Tahara M et al (2009) Safety and pharmacokinetics of panitumumab in Japanase ptients with advanced solid tumors. Int J Clin Oncol 14:307–314CrossRefPubMedGoogle Scholar
  30. 30.
    Kim R. Cetuximab and panitumumab: are they interchangeable? Lancet Oncol doi: 10.1016/S1470-2045(09)70312-2
  31. 31.
    Douillard JS, Cassidy J, Tabermero J et al (2009) Randomized phase 3 study on panitutumab with FOLFOX4 compared to FOLFOX alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. Eur J Cancer Suppl 7:6CrossRefGoogle Scholar
  32. 32.
    Peeters M, Price T, Hotko Y et al (2009) Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Eur J Cancer Suppl 7:2Google Scholar
  33. 33.
    Hecht JR, Mitchell E, Chidiac T et al (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27:672–680CrossRefPubMedGoogle Scholar
  34. 34.
    Tol J, Koopman M, Cats A et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563–572CrossRefPubMedGoogle Scholar
  35. 35.
    Berlin J, Van Cutsem E, Peeters M et al (2007) Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials. J Clin Oncol 25(suppl) abstract 4134Google Scholar
  36. 36.
    Bencardino K, Ronzoni M, Manzoni M et al (2008) In vivo biological effects of Panitumumab plus chemotherapy in advanced colorectal cancer patients. J Clin Oncol 26, abstract 14576Google Scholar
  37. 37.
    Hendlisz A, Marechal R, Durbecq V et al (2008) Modulation and prognostic value of epidermal growth factor receptor expression in circulating tumor cells during chemotherapy in patients with metastatic colon cancer. J Clin Oncol 26, abstract 15038Google Scholar
  38. 38.
    Freeman DJ, Juan T, Reiner M et al (2008) Association of KRAS mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 7:184–190CrossRefPubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2010

Authors and Affiliations

  1. 1.Ist Department of Pathology and Experimental Cancer ResearchSemmelweis UniversityBudapestHungary

Personalised recommendations